SCHEMBL17448776

SCHEMBL17448776

Cc1ccc(COC(C)c2ccc(C)cc2C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGXT P21549 2/20 0.41
IDO1 P14902 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NOD2 Q9HC29 1/20 0.36
MAOB P27338 2/20 0.36
TRPA1 O75762 1/20 0.35
CHRM1 P11229 1/20 0.35
SLC6A2 P23975 1/20 0.35
ADRA1A P35348 1/20 0.35
HTR2B P41595 1/20 0.35
RAB9A P51151 1/20 0.34
CASR P41180 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17448774 0.83 KDM4E (0.43) LMNAMAPTTRPA1CHRM1SLC6A2
SCHEMBL5669450 0.80 SMN1; SMN2 (0.39) LMNAMAPTTRPA1CHRM1SLC6A2
SCHEMBL14887945 0.80 IDO1 (0.40) AGXTIDO1CA1CA2CA9
SCHEMBL8750365 0.75 TRPA1 (0.43) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL8750414 0.74 TRPA1 (0.42) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL29599465 0.73 AGXT (0.54) AGXTIDO1CA1CA2CA9
SCHEMBL407132 0.73 AGXT (0.54) AGXTIDO1CA1CA2CA9
SCHEMBL11786210 0.72 TRPA1 (0.45) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL9073224 0.72 TRPA1 (0.41) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL11230641 0.72 AGXT (0.48) AGXTIDO1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160015707-A1 METHOD OF PROMOTING REMYELINATION UNIV CASE WESTERN RESERVE (US) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015707-A1 METHOD OF PROMOTING REMYELINATION CHAT, PMP22, MAG AGXT 4607/4885IDO1 1924/4885CA1 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.